Medpace (MEDP) CEO sells 14,747 and 6,047 shares in November

Medpace Holdings (MEDP) CEO and 10% owner August J. Troendle reported open‑market stock sales.

Rhea-AI Filing Summary

Medpace Holdings (MEDP) CEO and 10% owner August J. Troendle reported open‑market stock sales. On 11/14/2025, he sold 14,747 shares of Medpace common stock at a weighted average price of $595.26 per share, followed by a sale of 6,047 shares on 11/17/2025 at a weighted average price of $591.00 per share. The sales were executed pursuant to a limit order placed during an open trading window. After these transactions, he beneficially owns 893,368 shares directly and 4,733,019 shares indirectly through Medpace Investors, LLC, where he is the sole manager and controlling unit holder.

Insider Trade Summary

Net Seller: 20,794 shares

Net Sell 3 txns

Insider Troendle August J.

Role CEO

Sold 20,794 shs ($12.35M)

Type	Security	Shares	Price	Value
Sale	Common Stock	6,047	$591.00	$3.57M
Sale	Common Stock	14,747	$595.26	$8.78M
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 893,368 shares (Direct); Common Stock — 4,733,019 shares (Indirect, By Medpace Investors, LLC)

Footnotes (4)

1. F1. The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.
2. F2. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $590.00 to $600.51. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
3. F3. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $590.00 to $593.185. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.
4. F4. The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ("MPI") and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Medpace (MEDP) report on this Form 4?

The filing reports that August J. Troendle, a director, CEO and 10% owner of Medpace Holdings, Inc. (MEDP), sold Medpace common stock in two open‑market transactions in November 2025.

How many Medpace (MEDP) shares did August Troendle sell and at what prices?

On 11/14/2025, August Troendle sold 14,747 shares at a weighted average price of $595.26 per share, and on 11/17/2025 he sold 6,047 shares at a weighted average price of $591.00 per share.

How many Medpace (MEDP) shares does August Troendle still beneficially own after these sales?

Following the reported transactions, August Troendle beneficially owns 893,368 shares of Medpace common stock directly and 4,733,019 shares indirectly through Medpace Investors, LLC.

What is Medpace Investors, LLC in relation to August Troendle and MEDP stock?

Medpace Investors, LLC holds Medpace securities indirectly for August Troendle. He is the sole manager and controlling unit holder of this entity and has sole voting and investment control over the securities it holds.

Were the Medpace (MEDP) insider sales made under a specific trading instruction?

Yes. The explanation states that the transactions were effected pursuant to a limit order placed by the reporting person during an open window period.

Why are the reported Medpace (MEDP) sale prices shown as weighted averages?

The filing explains that each reported price is a weighted average because the shares were sold in multiple transactions within price ranges, and the reporting person will provide full pricing information to the issuer, any security holder, or SEC staff upon request.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/18/2025 - 04:51 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Troendle August J.

(Last) (First) (Middle)

C/O MEDPACE HOLDINGS, INC.

5375 MEDPACE WAY

(Street)

CINCINNATI OH 45227

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Medpace Holdings, Inc. [ MEDP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
11/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/14/2025		S(1)		14,747	D	$595.26(2)	899,415	D
Common Stock	11/17/2025		S(1)		6,047	D	$591(3)	893,368	D
Common Stock								4,733,019	I	By Medpace Investors, LLC(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.

2. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $590.00 to $600.51. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

3. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $590.00 to $593.185. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

4. The Reporting Person is the sole manager and controlling unit holder of Medpace Investors, LLC ("MPI") and has sole voting and investment control with respect to the securities held by MPI. The Reporting Person may be deemed to indirectly beneficially own the securities of the Issuer held by MPI but disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

Remarks:

	/s/ Stephen P. Ewald, Attorney-in-Fact for August J. Troendle	11/18/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.